Home › Funds › Bellevue Group AG › IONS

Bellevue Group AG position in IONS

IONIS PHARMACEUTICALS INC · Health Care

Bellevue Group AG reported holding 972,258 shares of IONS (IONIS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$77.1M, representing 1.62% of its reported portfolio and ranking #22 among its reported holdings. Bellevue Group AG has disclosed IONS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)972.26K sh
Reported value held$77.09M
Portfolio Weight1.62%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Bellevue Group AG's IONS position evolved

Bellevue Group AG first disclosed a stake in IONS in Q3 2023 at 9,233,700 shares (US$418.8M). The position peaked in Q4 2023 at 8,713,987 shares, worth US$440.8M. Across 12 filings, Bellevue Group AG increased the stake 0 time(s), trimmed it 7 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 972,258 shares valued at US$77.1M — a reduction of -846,407 shares quarter over quarter.. Notable position changes include a 62% trim in Q1 2026 (shares rose 6% over the following quarter), a 47% trim in Q2 2026 (shares fell 44% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 9.23M $418.84M New
Q4 2023 8.71M $440.84M Reduce
Q1 2024 8.30M $359.78M Reduce
Q2 2024 8.26M $393.69M Hold
Q3 2024 7.87M $315.45M Reduce
Q4 2024 7.87M $275.09M Hold
Q1 2025 7.85M $236.93M Hold
Q2 2025 7.85M $310.28M Hold
Q3 2025 6.24M $408.51M Reduce
Q4 2025 4.80M $379.90M Reduce
Q1 2026 1.82M $136.56M Reduce
Q2 2026 972.26K $77.09M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IONS and 13F data

IONS (IONIS PHARMACEUTICALS INC) is a Health Care company. 41 other funds we track also report a position in IONS — the largest reported positions include Two Sigma Investments (US$495.7M), TWO SIGMA ADVISERS, LP (US$241.5M), Tweedy, Browne Co LLC (US$180.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IONS

All IONS fund holders →

FAQ

How long has Bellevue Group AG held IONS?

Bellevue Group AG has disclosed IONS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Bellevue Group AG's current position in IONS?

As of Q2 2026, Bellevue Group AG holds 972.26K shares of IONS (IONIS PHARMACEUTICALS INC), valued at $77.09M, representing 1.62% of its reported portfolio and ranking #22.

Has Bellevue Group AG been buying or selling IONS?

In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in IONS. The position peaked in Q4 2023 at 8.71M shares.

Which other funds hold IONS?

Other major institutional holders of IONS include Two Sigma Investments, TWO SIGMA ADVISERS, LP, Tweedy, Browne Co LLC, among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.